Pulmonx, a company developing devices to treat emphysema, has raised $3 million in convertible promissory notes, according to VentureWire. The investors in this round are not known.

The Palo Alto, Calif. was founded in 1998, and its technology involves inserting a valve into the lung, shutting off the diseased portion of the lung. It has previously raised $27 million.